Abstract-Serum C-reactive protein (CRP) elevation predicts the development of heart failure in patients with hypertension. CRP activates macrophages and enhances oxidative stress. We hypothesize that CRP itself has a pathogenic role in the development of pressure overload-induced cardiac remodeling. Transgenic mice with human CRP overexpression (CRPtg) and nontransgenic littermates (CON) were subjected to transverse aortic constriction (TAC/CRPtg and TAC/CON) or sham operation (Sham/CRPtg and Sham/CON). One week after operation, in TAC/CRPtg, myocardial mRNA levels of interleukin (IL)-6, CD68, glutathione peroxidase-3 (GPx3), 47-kDa ␣-subunit of nicotinamide adenine dinucleotide phosphate oxidase (p47 phox ), and collagen-I, the number of infiltrating Mac-2-positive macrophages, nuclear localization of phosphorylated NF-B/p65 (p-p65) in cardiomyocytes, nuclear NF-B-DNA-binding activity, and reactive oxygen species (ROS) content were increased compared to those in TAC/CON. Cardiac fibrosis was more prominent in TAC/CRPtg compared to TAC/CON. Four weeks after operation, heart and lung weights, cardiomyocyte cross-sectional area, and the extent of cardiac fibrosis were greater in TAC/CON than in Sham/CON, and these differences were further augmented in TAC/CRPtg compared to TAC/CON. Left ventricular (LV) fractional shortening was less and LV end-diastolic pressure was higher in TAC/CRPtg than in TAC/CON. Myocardial mRNA levels of angiotensin type 1 receptor, atrial natriuretic factor, GPx3, p47 phox , collagen-I, and transforming growth factor (TGF)-␤1, the protein level of TGF-␤1, and the numbers of Mac-2-positive macrophages and p-p65-positive cells were higher in TAC/CRPtg than in TAC/CON. In conclusion, CRP itself may have a pathogenic role in the development of pressure overload-induced cardiac remodeling, possibly through enhanced inflammation and oxidative stress. C -reactive protein (CRP), which is an acute-phase protein, has been regarded as a risk factor or biomarker for cardiovascular disease, including coronary artery disease, hypertension, and heart failure. Elevation of serum CRP is associated with left ventricular (LV) dysfunction and is a predictor of mortality and morbidity in patients with heart failure, independent of ischemic/nonischemic etiology and other established cardiovascular risk factors. [1] [2] [3] Laboratory evidence suggests that CRP not only serves as a biomarker but also upregulates the angiotensin type 1 receptor (AT 1 R), 4 stimulates proinflammatory cytokine production, 5 and attenuates nitric oxide (NO) production. 6 In addition, pathological examination of endomyocardial biopsies in patients with dilated cardiomyopathy revealed that CRP is frequently present in the myocardium and colocalizes with complement and macrophages. 7 Furthermore, CRP is reported to promote fibrosis and inflammation in angiotensin II-induced cardiac remodeling. 8 These findings suggest that CRP itself may play some role in the development of LV dysfunction and remodeling.
C
-reactive protein (CRP), which is an acute-phase protein, has been regarded as a risk factor or biomarker for cardiovascular disease, including coronary artery disease, hypertension, and heart failure. Elevation of serum CRP is associated with left ventricular (LV) dysfunction and is a predictor of mortality and morbidity in patients with heart failure, independent of ischemic/nonischemic etiology and other established cardiovascular risk factors. [1] [2] [3] Laboratory evidence suggests that CRP not only serves as a biomarker but also upregulates the angiotensin type 1 receptor (AT 1 R), 4 stimulates proinflammatory cytokine production, 5 and attenuates nitric oxide (NO) production. 6 In addition, pathological examination of endomyocardial biopsies in patients with dilated cardiomyopathy revealed that CRP is frequently present in the myocardium and colocalizes with complement and macrophages. 7 Furthermore, CRP is reported to promote fibrosis and inflammation in angiotensin II-induced cardiac remodeling. 8 These findings suggest that CRP itself may play some role in the development of LV dysfunction and remodeling.
Human CRP is mainly produced in the liver in response to infection, acute injury, or other inflammatory stimuli. Although CRP is not an acute-phase reactant in mice and is minimally expressed, human CRP can activate complement (A, B, and C) in mice 9 and bind to mouse Fc␥ receptor I (Fc␥RI) and Fc␥RIIb, which provoke inflammation and oxidative stress. 10 Therefore, transgenic mice carrying the human CRP gene provide a viable model to investigate the role of CRP in vivo. 9 We investigated the role of CRP in pressure overloadinduced cardiac remodeling, especially its effect on inflamma-tion and oxidative stress, using human CRP-overexpressing transgenic (CRPtg) mice.
Materials and Methods
A detailed Methods section can be found in the online Data Supplement (available at http://hyper.ahajournals.org).
Experimental Animals
CRPtg mice (C57BL/6 background) were generated under the control of the CAG promoter to induce ubiquitous transgene expression as described previously. 11 Male CRPtg (9 to 12 weeks of age) and their age-matched male nontransgenic littermates (CON) were used.
Mouse Model of Transverse Aortic Constriction and Experimental Study Protocol
Twenty-eight CRPtg and 28 CON underwent transverse aortic constriction (TAC) operation. The TAC procedure was reported in a previous study, 12 as described in the online Data Supplement Methods section. Mice were euthanized 1 and 4 weeks after TAC or sham operation. Cardiac tissue was collected for gene expression quantification, protein analysis, and histological examination.
Additional Methods
The expanded Methods section in the Online Data Supplement contains information on the hemodynamic measurements, echocardiographic analyses, immunoblotting, tissue analyses, immunohistochemical staining, dihydroethidium (DHE) staining, electrophoretic mobility shift assay (EMSA), measurement of serum CRP, measurement of CRP, tumor necrosis factor (TNF)-␣, NO, inducible NO synthase (iNOS) in cardiac tissue, and quantification of gene expression by real-time polymerase chain reaction (RT-PCR).
Statistical Analysis
All continuous data were expressed as meanϮSEM. The statistical significance of differences between multiple groups was determined using one-way ANOVA and post hoc analysis with the Bonferroni test. A probability value of Ͻ0.05 was considered to be significant. All statistical analyses were performed using the SPSS 15.0 statistical software package for Windows (SPSS Inc.).
Results

CRPtg Mice
Gene expression in the heart was confirmed by RT-PCR with primers for human CRP ( Figure S1A ). Protein expression in the heart was also confirmed by immunoblotting of LV homogenates with antibodies recognizing human CRP (Figure S1B ) and immunohistochemical staining ( Figure S1C and S1D).
Body and Organ Weights, CRP Levels, and Cardiac Function
The body, heart, lung weights, and serum and cardiac CRP levels are summarized in Table S1 . Mice with TAC operation showed increased heart weight 1 week after operation, compared to that in sham-operated mice, but there was no difference between TAC/CRPtg and TAC/CON. Four weeks after TAC operation, the weights of the heart and lungs were further increased compared to those in sham-operated mice, and these parameters, lung weight/body weight ratio and lung wet/dry ratio in TAC/CRPtg, were significantly higher than those in TAC/CON. Both serum and cardiac CRP levels in CRPtg were significantly increased compared to those in CON; however, no difference was noted between CRPtg with and without TAC operation.
The echocardiographic data are shown in Table S2 . One week after operation, there were no significant differences in echocardiographic parameters among the four groups. Four weeks after operation, LV dimensions and wall thickness were greater and LV fractional shortening and velocity of circumferential fiber shortening were smaller in TACoperated mice compared to their sham-operated counterparts. These changes were further augmented in TAC/CRPtg compared to TAC/CON.
Hemodynamic data are shown in Table S3 . Right carotid systolic arterial pressure and LV systolic pressure 1 and 4 weeks after TAC operation were increased compared to those in sham-operated mice. Pressure gradient across the aortic constriction 1 and 4 weeks after TAC operation was comparable between TAC/CRPtg and TAC/CON. LV end-diastolic pressure 4 weeks after TAC operation was significantly higher in TAC/CRPtg than in TAC/CON.
Cardiac Hypertrophy and Fibrosis
Hematoxylin-eosin staining of the heart showed that cardiomyocyte cross-sectional area (CSA) was greater in TAC/ CON than in Sham/CON 1 and 4 weeks after operation. The increase in CSA was further augmented in TAC/CRPtg compared with TAC/CON 4 weeks after operation (Figure 1 ). Triphenyltetrazolium chloride (TTC) staining 1 and 4 weeks after TAC operation showed that there was no TTC-positive area in TAC/CRPtg and TAC/CON.
Staining with Masson's trichrome showed cardiac fibrosis in both the interstitial and perivascular areas 1 week after TAC operation (Figure 2 ). There was a significantly increased percentage of area fraction in both the interstitial and perivascular areas of the LV in TAC/CRPtg compared to TAC/CON. Four weeks after operation, the percentage of area fraction in the perivascular area of the LV was markedly higher in TAC/CRPtg than in TAC/CON, although there was no significant difference in the interstitial area between TAC/CRPtg and TAC/CON ( Figure 2 ).
Myocardial Expression of Hypertrophic and Fibrotic Markers
Myocardial mRNA expression of atrial natriuretic factor (ANF) in TAC/CRPtg was increased 1 and 4 weeks after operation compared to that in Sham/CON. ANF expression in TAC/CRPtg 4 weeks after operation was significantly higher than that in TAC/CON ( Figure 3A ). Myocardial mRNA expression of B-type natriuretic peptide 4 weeks after operation was higher in TAC/CRPtg than in Sham/CRPtg or TAC/CON ( Figure 3B ). Myocardial mRNA expression of collagen-I and transforming growth factor (TGF)-␤1 1 and 4 weeks after operation was significantly higher in TAC/CRPtg than in TAC/CON or sham-operated mice ( Figure 3C and 3E). Myocardial connective tissue growth factor mRNA level 4 weeks after operation was higher in TAC/CRPtg than in TAC/CON or sham-operated mice ( Figure 3D ). Myocardial protein expression of TGF-␤1 in TAC/CON 4 weeks after operation was increased compared to that in Sham/CON. Its level was higher in TAC/CRPtg than in TAC/CON ( Figure 3F ).
Inflammatory Cytokines, Oxidative Stress, and Renin-Angiotensin System
Expression of interleukin (IL)-6 mRNA in myocardial tissue of TAC/CRPtg was markedly elevated compared to that in Sham/CRPtg or TAC/CON, peaking 1 week after operation.
Its expression was persistently elevated in TAC/CRPtg 4 weeks after operation compared to that in Sham/CRPtg or TAC/CON ( Figure 4A ). In contrast, the level of TNF-␣ mRNA showed little change in either TAC/CON or TAC/ CRPtg 1 week after operation but was significantly higher in TAC/CRPtg than in either Sham/CRPtg or TAC/CON 4 weeks after operation ( Figure 4A ). Furthermore, the protein expression of TNF-␣ was higher in TAC/CRPtg compared to TAC/CON at 4 weeks after TAC operation ( Figure 4B ). The oxidative stress markers glutathione peroxidase-3 (GPx3) and 47-kDa ␣-subunit of nicotinamide adenine dinucleotide phosphate oxidase (p47 phox ) showed a similar expression pattern to that of IL-6. Myocardial mRNA levels of both factors were significantly elevated in TAC/CRPtg compared to those in either TAC/CON or sham-operated mice 1 week after operation, and these differences remained 4 weeks after operation ( Figure 4C ). DHE staining showed that reactive oxygen species (ROS) content was greater in TAC/ CRPtg than in TAC/CON at 1 week after TAC operation ( Figure 4D ).
Expression of both angiotensinogen and AT 1 R mRNA in myocardial tissue was significantly higher in both TAC/ CRPtg and TAC/CON compared to that in their shamoperated counterparts. One week after operation, myocardial mRNA expression of both factors was comparable between TAC/CRPtg and TAC/CON. However, 4 weeks after operation, it was significantly higher in TAC/CRPtg than in TAC/CON ( Figure 4E ). vated in TAC/CRPtg compared to that in TAC/CON, peaking at 1 week after TAC operation ( Figure S2A ). NO and iNOS expression were significantly decreased in TAC/CRPtg compared to TAC/CON at both 1 and 4 weeks after TAC operation ( Figure S2B ).
Macrophage Infiltration and Nuclear Factor-B/p65 Activation in Cardiomyocytes
Immunohistochemical staining showed an increase in the number of infiltrating Mac-2-positive macrophages in TAC/ CRPtg compared to TAC/CON or Sham/CRPtg, peaking 1 week after TAC operation ( Figure 5A and 5B). Myocardial CD68 expression 1 week after operation was increased in TAC-operated mice compared to sham-operated mice. TAC/ CRPtg mice had higher CD68 expression 1 week after operation compared to TAC/CON. The number of nuclear localization of phosphorylated nuclear factor-B (NF-B)/p65 (p-p65)-positive cardiomyocytes was higher in TAC/CRPtg than in sham-operated mice or TAC/CON 1 week after operation, and it remained elevated 4 weeks after operation in TAC/CRPtg compared to TAC/CON ( Figure 6A and 6B). In addition, EMSA demonstrated that nuclear NF-B-DNA-binding activity was significantly increased in TAC/CRPtg 1 week after TAC operation compared to the other groups ( Figure 6C ).
Discussion
The present study demonstrated direct evidence of the pathogenic role of human CRP in pressure overload-induced cardiac remodeling, including a fall in fractional shortening and velocity of circumferential fiber shortening, promoted cardiac hypertrophy and fibrosis, and enhanced inflammation, oxidative stress, and renin-angiotensin system (RAS) activation. Interestingly, the deterioration of cardiac remodeling by CRP overexpression was preceded by an increase in macrophage infiltration, phosphorylated NF-B/p65 in cardiomyocytes, myocardial expression of inflammatory cytokines, oxidative stress and p38 MAPK signaling, and a decrease in NO production. These findings suggest that CRP may play an important role in pressure overload-induced cardiac remodeling possibly through enhanced inflammation and oxidative stress.
Cardiac hypertrophy is considered to be an adaptive mechanism compensating for a chronic increase in pressure overload mechanical stress. However, it can become maladaptive if cardiac fibrosis develops and compensated hypertrophy evolves into cardiac failure, which is characterized by inadequate cardiac pumping activity. 13 As well as neurohormonal changes, activation of inflammatory signaling pathways by proinflammatory cytokines, such as TNF-␣ and IL-1␤, has been considered to promote both cardiac hypertrophy and fibrosis. 14, 15 Conversely, inhibition of inflammatory signaling by NF-B ablation in TNF-␣-overexpressing transgenic mice can attenuate the development of pressure overload-induced cardiac hypertrophy. 16 Xia et al 17 demonstrated upregulation of proinflammatory cytokines and leukocyte infiltration in pressure-overloaded myocardium, in association with perivascular fibrotic changes and cardiac hypertrophy, using a mouse TAC model. Although the precise mechanism causing inflammatory changes in the pressure-overloaded myocardium has not been clarified, mechanical strain on the cardiomyocyte is known to induce production of IL-6, which activates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway and is related to myocardial hypertrophy. 18 Mechanical strain of the arterial wall is also known to induce production of ROS, proinflammatory cytokines including myocyte chemoattractant protein-1 (MCP-1), and growth factors including TGF-␤1, as well as RAS activation. 19, 20 MCP-1 overexpression induced by mechanical stress and RAS activation result in macrophage infiltration and accelerate local inflammation in a positive-feedback manner. 21 Therefore, inflammation may play a pivotal role in the process of pressure overloadinduced cardiac remodeling. In fact, an inflammatory marker, serum CRP, is known to increase in heart failure patients with nonischemic etiology including hypertension and is a predictor of long-term clinical outcomes. 2 In our results, p38 MAPK activation was enhanced in TAC/CON and further augmented in TAC/CRPtg. p38 MAPK is activated by several types of stress and inflammation and is reported to play an important role in the development of myocardial hypertrophy in a rodent chronic pressureoverloaded model. 22 Additionally, NO production was reduced in TAC/CON and further decreased in TAC/CRPtg. Previous study demonstrated that NO production is impaired in the CRP overexpression mice model. 23 Therefore, our result suggests that CRP may activate p38 MAPK and impair NO production via enhancing the inflammatory response and oxidative stress.
CRP is a highly conserved acute-phase protein, secreted predominantly from the liver in response to proinflammatory cytokines, complement activation products, and hormones. 9 CRP shares many functional activities with IgG molecules, including the binding of specific ligands, opsonization of foreign molecules, and binding to Fc␥Rs on macrophages and neutrophils. Activation of Fc␥R signaling results in production of proinflammatory cytokines and ROS. 24 In the setting of cardiovascular disease, elevated serum CRP is known to be associated with acceleration of atherosclerosis, 25 increased thrombosis, 26 exaggerated neointima formation after vascular injury, 27 and mural thrombosis, 28 cardiac rupture, and adverse LV remodeling 29 after myocardial infarction. Thus, CRP plays an active role originally in protecting the host from infection and injury; however, it may be related to the pathogenesis of cardiovascular complications after endogenous vascular and myocardial injury.
In the present study, overexpression of human CRP exacerbated pressure overload-induced cardiac remodeling in association with increased expression of proinflammatory cytokines, oxidative stress, p38 MAPK signaling, RAS activation, and impaired NO production. These factors synergistically activate each other and form a vicious circle during the process of cardiac remodeling. CRP overexpression might exert its effect by amplifying this vicious circle through activating each key component. The current data revealed a significant increase in the number of macrophages, NF-B/ p65-expressing myocardial cells, nuclear NF-B-DNAbinding activity, and proinflammatory cytokine expression in the LV of CRPtg preceding the development of cardiac dysfunction after TAC operation. CRP is known to activate monocytes, macrophages, neutrophils, and endothelial cells by binding to their IgG Fc␥Rs. 10, 27, 30 Moreover, CRP is capable of enhancing production of proinflammatory cytokines, including IL-6 and TNF-␣, in cultured monocytes via an NF-B-dependent mechanism. 31 These findings suggest that the effects of CRP may be mediated through activation of immunocompetent cells infiltrating into the pressureoverloaded myocardium. It could explain our observation that, in sham-operated mice in which inflammatory cell infiltration was almost absent, CRP overexpression did not show any adverse effect on cardiac function. A previous study showed that CRP itself increased fibrotic and inflammatory markers in mice fibroblasts in vitro. 8 However, the major source of proinflammatory markers in vivo is inflammatory cells, which infiltrated into the pressure-overloaded myocardium prior to the development of cardiac fibrosis. Therefore, increased expression of fibrotic and inflammatory markers in cardiac fibroblasts might contribute less to the development of pressure overload-induced cardiac remodeling.
CRP also promoted the expression of a profibrotic factor, TGF-␤1, which was increased in response to pressure overload. Increased TGF-␤1 may trigger the TGF-␤/Smad pathway, activate fibroblasts, 8 and contribute to the promotion of cardiac fibrosis. Since the combination of hypertrophy and fibrosis causes a progressive decline in both systolic and diastolic function, increased CRP expression could be one of the determinants leading to decompensated heart failure in pressure overload.
To examine the relationship between accelerated remodeling and overexpression of human CRP, we performed antiinflammatory therapy using eicosapentaenoic acid (EPA), which might prevent the development and progression of heart failure, especially in pressure overload-induced cardiac remodeling. 32 A recent clinical study, the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-heart failure) trial, showed that a low dose of EPA administered to heart failure patients significantly decreased mortality compared to placebo. 33 One of the possible mechanisms by which EPA could prevent the development and progression of heart failure is its strong antiinflammatory activity. 32 We treated mice with 7% EPA for 2 weeks before TAC operation and then 1 or 4 weeks after operation. Treatment with 7% EPA for 4 weeks after TAC operation resulted in reduced heart and lung weights, increased LV fractional shortening, and decreased LV end diastolic pressure, cross-sectional area, and extent of cardiac fibrosis compared to TAC/CRPtg without EPA treatment. These changes were preceded by decreased IL-6 and TNF-␣ mRNA expression, Mac-2-positive cell infiltration, p-p65-positive cardiomyocyte count, and oxidative stress (GPx3 and p47 phox mRNA expression) 1 week after TAC operation (data not shown). These results suggest that EPA may suppress the adverse effects of CRP overexpression on pressure overloadinduced cardiac remodeling, possibly through attenuation of the enhanced inflammatory response and oxidative stress. These findings also support the importance of an inflammation-mediated mechanism in the process of pressure overload-induced cardiac remodeling.
Perspectives
Our results showed CRP may play a pathogenic role in the progression of cardiac remodeling, thus CRP could be a candidate for a therapeutic target. Direct inhibition of CRP may reduce or eliminate the progressive inflammation, fibrosis, and hypertrophy during pressure overload-induced cardiac remodeling. This therapeutic strategy could be effective in patients with hypertension and aortic valve stenosis associated with an increased serum CRP level.
In conclusion, continuous overexpression of human CRP in mice adversely affect pressure overload-induced cardiac remodeling preceded by enhanced inflammation and oxidative stress.
CRP plays a pathogenic role in cardiac remodeling and could be a therapeutic target for the treatment of heart failure induced by pressure overload. 
Echocardiography and Hemodynamic Measurements
Echocardiographic and hemodynamic studies were performed one week and four weeks after Cardiac catheterization studies were performed using a 1.4 French micromanometer-tipped catheter (SPR-671, Miller Instruments, Houston, TX) under sedation with ketamine (50 mg/kg, IP) and 2% xylazine (6 mg/kg, IP) with spontaneous respiration as previously described. 1 LV systolic pressure and LV end-diastolic pressure were measured using analysis software (PowerLab, AD Instruments, Bella Vista, NSW, Australia). In addition, this catheter was inserted into the femoral artery to determine the pressure gradient across the aortic constriction.
Histological Analysis
The ventricular tissue was fixed in formalin and embedded in paraffin using standard histological procedures. The tissue was cut to yield 5-µm thick cross sections. The sections were subsequently stained with hematoxylin and eosin (HE) to determine cardiomyocyte short axis cross-sectional area (CSA) in the LV, or Masson's trichrome stain to determine the degree of fibrosis. CSA and percent area fraction were measured using ImageJ software (version 1.38x, National Institutes of Health). Triphenyltetrazolium chloride staining was also performed to rule out microinfarction one and four weeks after TAC operation.
Quantitative Real Time Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from heart tissue by a modification of the acid guanidinium thiocyanate and phenol/chloroform extraction method as previously described. 1 Realtime quantitative PCR of each sample was carried out with TaqMan Gene Expression Assays kits and an ABI Prism™ 7700 Sequence Detection System (Applied Biosystems, Foster City, CA), based on methods described previously. AACTCCCTCAAGATTGTCAGCAA; reverse primer: GTGGTCATGAGCCCTTCCA;
TaqMan probe: CTGCACCACCAACTGCTTAGCCCC.
Immunoblotting Analysis
Western blotting analysis was conducted to measure the expression of TGF-β1, phosphorylated p38 Mitogen-Activated Protein Kinase (MAPK) and p38 MAPK protein in LV tissue. Frozen tissue for western blotting was homogenized in cell lysis buffer (Cell Signaling Technology, Danvers, MA) containing 1% Triton X-100 and protease inhibitors. The homogenate was centrifuged at 16,000 × g for 30 minutes at 4°C, and the supernatant liquid was collected. Protein concentrations were measured and immunoblotting analysis was carried out as previously described.
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Immunohistochemical Analysis
Sections to be stained for Mac-2 were incubated for 30 minutes at room temperature in 1%
hydrogen peroxide in methanol to quench endogenous peroxidase activity. The sections were incubated with the primary antibody (CL8942AP, Cedarlane, Ontario, Canada) for 1 hour. The sections were then incubated in a mixture containing 25 µL normal mouse serum, 5 µL biotinylated anti-rat IgG (BA-9400, Vector Laboratories, Burlingame, CA) and 500 µL phosphate buffered saline (PBS) for 30 minutes. The sections to be stained for NF-κB/p65 underwent antigen retrieval by incubation in a microwave for 5 minutes in 10 mM citrate buffer solution (pH 6.0), followed by treatment with 1% hydrogen peroxide, as described above. The sections were incubated with the primary antibody (sc-3272, Santa Cruz Biotech., Santa Cruz, CA) for 1 hour. The sections were then incubated in Envision (anti-rabbit) for 30 minutes.
Antibody binding was visualized using the avidin-biotin complex method according to the manufacturer's instructions (Vectastain ABC; Vector). The primary antibody was omitted from these protocols as a negative control. The sections were subsequently counterstained with -HE.
Triphenyl tetrazolium chloride (TTC) staining
Working dye solution (1% TTC in PBS) (SIGMA, St. Louis, MO) was prepared immediately before use and used for one batch of experiments. Dissected tissues were incubated with the dye for 5 minutes. After washing the slides with PBS for 5 minutes, stained slides were mounted with malinol mountant.
Dihydroethidium (DHE) staining
Stock solution of DHE dye (SIGMA, St. Louis, MO) was reconstituted using dimethyl 
Measurement of TNF-α by Fluorescent Microspheres
Expression of TNF-α was measured by suspension assay using a MILLIPLEX MAP Mouse Cytokine/ Chemokine Kit and Luminex xMAP™ system (Luminex), which is a common procedure for measurement of TNF-α for Luminex analysis. All samples were run in duplicate according to the manufacturer's instructions without modification. Total proteins from LV tissue were incubated with anti-TNF-α immobilized beads for 1 hour at room temperature. The beads were washed with wash buffer to remove any unbound reagents and reacted with a secondary biotinylated detection antibody that recognizes the TNF-α molecule for 30 minutes at room temperature. Furthermore, streptavidin-PE was added to each well containing the detection antibodies, and incubated for 30 minutes at room temperature. After washing with beads as described above, all the precipitates were resuspended with 150 µL sheath fluid for Luminex 200™ system analysis. Fifty events of each subset of microspheres were analyzed for each experiment.
Measurement of Nitric Oxide (NO) Production
NO production was assayed by measuring nitrite in total proteins extracted from LV tissue using a Nitric Oxide Quantitation Kit (ACTIVE MOTIF, Carlsbad, CA). Briefly, nitrate in the sample was converted to nitrite by adding nitrate reductase and cofactors. Total proteins were mixed with an equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 5% phosphoric acid) and then incubated at room temperature for 20 minutes. The concentration of nitrite was then determined by measuring the absorbance at 540 nm and comparing the value to a standard curve generated using sodium nitrate (NaNO 3 ) or sodium nitrite (NaNO 2 ).
Inducible NO Synthase (iNOS) Enzyme-Linked Immunosorbent Assay (ELISA)
An ELISA plate (Cell Signaling, Danvers, MA) precoated with iNOS antibody was used to evaluate NOS expression level. First, 50 µg (0.5 mg/mL × 100 µL) of each sample and iNOS standard were added to wells, and the plates were incubated for 2 hours. Next, iNOS detection antibody and HRP linked anti-mouse IgG were added to each well, and the plates were incubated for an additional 1 hour. TMB substrate solution was added to the wells, after which the plates were then incubated for 30 minutes in the dark. Finally, the reaction was stopped by adding 2NH 3 PO 4 as stop solution, and then the absorbance was measured at 450 nm. One week after TAC (n = 6) (n = 6) (n = 6) (n = 6) 
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